ReviewScientifica2012
Tissue factor structure and function.
Review in Scientifica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 69 citations in OpenAlex.
- Trial
- Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Article
- Enhancing Tissue Factor Production: The Role of N-Glycosylation and ERAD Pathway Modulation.Protein and peptide letters · 2025Article
- Activated Factor VII-Antithrombin Complex, a Biomarker of Tissue Factor-Related Pathways in Different Clinical Settings: A Narrative Review from Cardiovascular Diseases to Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis.Current molecular medicine · 2024Review
- Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system.Research and practice in thrombosis and haemostasis · 2023Article
- Elevated Levels of Procoagulant Microvesicles and Tissue-Factor Bearing Microvesicles in Malaria Patients.International journal of general medicine · 2023Article
- Genetic duplication of tissue factor reveals subfunctionalization in venous and arterial hemostasis.PLoS genetics · 2022Article
- The Therapeutic Potential of Anticoagulation in Organ Fibrosis.Frontiers in medicine · 2022Review
- Liver injury associated with acute pancreatitis: The current status of clinical evaluation and involved mechanisms.World journal of clinical cases · 2021Review
- De-Palmitoylation of Tissue Factor Regulates Its Activity, Phosphorylation and Cellular Functions.Cancers · 2021Article
- PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability.International journal of molecular sciences · 2021Article
- Inflammasome-Dependent Coagulation Activation in Sepsis.Frontiers in immunology · 2021Review
- Effect of Freezing Time on Tissue Factor Activity and Macronutrients of Human Milk.The protein journal · 2020Article
- Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.Research and practice in thrombosis and haemostasis · 2020Article
- Antiviral anticoagulation.Research and practice in thrombosis and haemostasis · 2020Review
- Characterization of the inhibition mechanism of a tissuefactor inhibiting single-chain variable fragment: a combined computational approach.Journal of molecular modeling · 2020Article
- Correlating Fibrinogen Consumption and Profiles of Inflammatory Molecules in Human Envenomation's byFrontiers in immunology · 2020Article
- Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature.Journal of porphyrins and phthalocyanines · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Tissue factor (TF) is an integral membrane protein that is essential to life. It is a component of the factor VIIa-TF complex enzyme and plays a primary role in both normal hemostasis and thrombosis. With a vascular injury, TF becomes exposed to blood and binds plasma factor VIIa, and the resulting complex initiates a series of enzymatic reactions leading to clot formation and vascular sealing. Many cells, both healthy, and tumor cells, produce detectable amounts of TF, especially when they are stimulated by various agents. Despite the relative simplicity and small size of TF, there are numerous contradictory reports about the synthesis and presentation of TF on blood cells and circulation in normal blood either on microparticles or as a soluble protein. Another subject of controversy is related to the structure/function of TF. It has been almost commonly accepted that cell-surface-associated TF has low (if any) activity, that is, is "encrypted" and requires specific conditions/reagents to become active, that is, "decrypted." However there is a lack of agreement related to the mechanism and processes leading to alterations in TF function. In this paper TF structure, presentation, and function, and controversies concerning these features are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.